HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response
Background/Aims: Cisplatin-based treatment is first-line chemotherapy for several cancers including ovarian cancer. The development of cisplatin resistance results in treatment failure, but the underlying mechanisms are not fully understood. Histone deacetylases (HDACs) are a large family of enzymes...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Cell Physiol Biochem Press GmbH & Co KG
2018-08-01
|
| Serie: | Cellular Physiology and Biochemistry |
| Soggetti: | |
| Accesso online: | https://www.karger.com/Article/FullText/492260 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|